Evidence map›Paper›PMID 40645586›Full record

ArticleSLAS discovery : advancing life sciences R & D2025

A scalable human gut-immune co-culture model for evaluating inflammatory bowel disease anti-inflammatory therapies.

Swetha Peddibhotla, Lauren A Boone, Earnest L Taylor, Bryan E McQueen, Elizabeth M Boazak

Abstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Swetha PeddibhotlaAltis Biosystems, Inc. Durham, USA.
Lauren A BooneAltis Biosystems, Inc. Durham, USA.
Earnest L TaylorAltis Biosystems, Inc. Durham, USA.
Bryan E McQueenAltis Biosystems, Inc. Durham, USA.
Elizabeth M BoazakAltis Biosystems, Inc. Durham, USA. Electronic address: liz@altisbiosystems.com.

Funding

InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammationR44TR004234 · NCATS · ALTIS BIOSYSTEMS, INC. · PI SIMS, CHRISTOPHER ELDRIDGE, THELIN, BILL · 2022 to 2023
$2.0M
NCATS NIH HHS R44 TR004234
6 · The paper itself

Abstract

Current treatments for inflammatory bowel disease (IBD) are often ineffective long-term, as many patients ultimately become unresponsive to anti-inflammatory drugs. The need for improved therapeutics is urgent. Animal models utilized for drug development are limited by interspecies variability and poor translatability. However, most in vitro models lack the sophistication to model the key interplay of the immune system with the intestinal epithelium in line with the known role of the immune system in the etiology of the disease. To address this gap, we developed a primary intestinal epithelial cell co-culture system to incorporate elements of innate immune signaling. This system models immune-epithelial interactions using RepliGut

Indexed as

Anti-Inflammatory AgentsInflammatory Bowel DiseasesCell SurvivalCoculture TechniquesCytokinesEpithelial CellsHumansIntestinal MucosaLipopolysaccharidesMacrophagesPiperidinesPyrimidinesAnti-Inflammatory AgentsCytokinesLipopolysaccharidesPiperidinesPyrimidinestofacitinibCo-culture modelImmune-epithelial interactionInflammatory bowel disease (IBD)Primary human intestinal cellsTHP-1 macrophages

Identifiers

PMID40645586
PMCPMC12646107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.